[Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile]

Rev Med Chil. 2005 Mar;133(3):295-301. doi: 10.4067/s0034-98872005000300004. Epub 2005 May 5.
[Article in Spanish]

Abstract

Background: Resistance to antiretroviral therapy is a determining factor for therapeutic failure in HIV/AIDS. The prevalence of primary resistance (i.e. in those patients that have not received treatment) varies in different parts of the world.

Aim: To study the prevalence of primary resistance to antiretroviral drugs in patients living in Northern Santiago.

Patients and methods: Viral load, lymphocyte subpopulations by flow cytometry and genotypic resistance testing were assessed in blood samples from 60 HIV-1 infected patients (mean age 37 years, 54 male).

Results: Mean CD4 cell count and viral load was 200 cells/ml and 142,840 RNA copies/ml respectively. Ten mutations were identified: V179D, L10I/V, M361, L63P, A71T/V, Y115F, V118I and K20R. None of these mutations is associated to a high degree of resistance to reverse transcriptase inhibitors, nucleoside analogs (NRTI), non nucleoside analogs (NNRTI) or viral protease inhibitors.

Conclusions: This is a first approach to study antiretroviral resistance in Chilean patients. This study must be amplified, since the prevalence of resistance may experience changes with time.

Publication types

  • English Abstract

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Chile / epidemiology
  • Drug Resistance, Viral / genetics*
  • Female
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Reverse Transcriptase / genetics
  • HIV-1* / genetics
  • Humans
  • Male
  • Middle Aged
  • Mutation

Substances

  • HIV Reverse Transcriptase